伊立替康联合放化疗作为局部晚期直肠癌术前治疗(ARISTOTLE):多中心、开放标签、3期随机对照试验
ARISTOTLE研究纳入564例MRI定义的局部晚期直肠癌患者,随机接受卡培他滨联合放疗或再加伊立替康。结论:加用伊立替康未改善结局,不应与放疗加卡培他滨联用。
要点
- 伊立替康组3级及以上不良事件发生率更高(78% vs 52%)。
- 伊立替康组完成45Gy放疗和卡培他滨计划剂量的比例更低。
核心结论
- 对于MRI定义的高危局部晚期直肠癌,在标准治疗基础上加用伊立替康未改善结局,不应与放疗加卡培他滨联用。
研究设计与样本
- ARISTOTLE为多中心、开放标签、平行设计、3期随机对照试验,在英国75家医院开展。
- 589例患者随机分组,564例纳入改良意向治疗分析(标准治疗组284例,伊立替康组280例)。
- 患者为≥18岁、MRI定义局部晚期直肠癌(威胁或侵犯切除边缘)且无转移。
- 随机1:1接受术前放疗45Gy/25次,联合卡培他滨900mg/m2(标准组)或卡培他滨650mg/m2加伊立替康60mg/m2(伊立替康组)。
主要发现
- 伊立替康组死亡88例(31%),标准组92例(32%);直肠癌为主要原因(67% vs 73%)。
- 伊立替康组3级及以上不良事件215例(78%),标准组148例(52%);血液学检查异常分别为235例(85%)和109例(39%)。
- 伊立替康组腹泻38例(14%),标准组10例(4%);淋巴细胞计数下降181例(66%)vs 100例(35%)。
- 治疗相关死亡5例:伊立替康组3例(血栓栓塞事件2例,多器官衰竭加脓毒症1例),标准组2例(心脏骤停1例,发热性中性粒细胞减少1例)。
关键数值与推荐
- 伊立替康组接受45Gy放疗的比例为208/276(75%),标准组为251/283(89%)。
- 伊立替康组接受至少90%计划卡培他滨剂量的比例为187/276(68%),标准组为253/283(89%)。
- mrT3肿瘤比例:标准组223例(79%),伊立替康组212例(76%);mrT4肿瘤比例分别为44例(15%)和45例(16%)。
临床怎么用
- 对于MRI定义的高危局部晚期直肠癌,不应在放疗加卡培他滨的基础上加用伊立替康。
- 应继续采用标准术前放化疗方案,避免因加用伊立替康导致毒性增加和治疗完成度下降。
局限性
- 研究为开放标签设计,患者和治疗医生未设盲。
- 未收集种族数据。
- 伊立替康组放疗和卡培他滨剂量完成度较低,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Locally advanced rectal cancer is routinely treated with neoadjuvant radiotherapy. Concomitant systemic anticancer therapy with standard fluoropyrimidines has not generally improved outcomes. Small studies reported high pathological complete response rates and acceptable toxicity using irinotecan and fluoropyrimidine chemoradiation. We aimed to explore the effect of the addition of concomitant irinotecan to standard-of-care chemoradiotherapy in patients with locally advanced rectal cancer. METHODS: ARISTOTLE is a multicentre, open-label, parallel-design, phase 3, randomised controlled trial conducted at 75 UK hospital sites treating patients with rectal cancer. Patients were eligible if they were aged at least 18 years with MRI-defined, locally advanced rectal cancer threatening or involving resection margins without metastases. Patients were randomly assigned (1:1) to preoperative radiotherapy 45 Gy in 25 daily fractions, combined with either oral capecitabine 900 mg/m2 alone twice daily on weekdays (standard-of-care group) or oral capecitabine 650 mg/m2 twice daily on weekdays plus intravenous irinotecan 60 mg/m2 once weekly in weeks 1-4 (irinotecan group). Randomisation was done centrally, with allocation concealed to investigators; masking of patients and treating clinicians was not feasible. Stratification was by radiotherapy centre, mesorectal fascia involvement, and presence or absence of equivocal metastatic disease. The primary endpoint was disease-free survival, with analysis done on a modified intention-to-treat basis (ie, all eligible patients who were randomly assigned to treatment). Safety analyses were conducted in all patients who started protocol treatment (as-treated population). For time-to-event endpoints, patients without an event were censored at the date they were last known to be alive; missing radiological and pathological response assessments were classified as non-response. The study is registered with EudraCT, 2008-005782-59, and is complete. FINDINGS: Between Oct 25, 2011, and July 5, 2018, 589 patients were randomly assigned to treatment; after exclusions, 564 were included in the modified intention-to-treat population (284 in the standard-of-care group and 280 in the irinotecan group). 370 (66%) patients were male, 194 (34%) were female, and median age was 61 years (IQR 54-68); ethnicity data were not collected. Staging in both groups was similar: 223 (79%) patients in the standard-of-care group and 212 (76%) in the irinotecan group had mrT3 tumours; 44 (15%) and 45 (16%) had mrT4 tumours, respectively. Patients in the irinotecan group were less likely to receive 45 Gy radiotherapy than in the standard-of-care group (208 [75%] of 276 vs 251 [89%] of 283) or at least 90% of the planned capecitabine dose (187 [68%] of 276 vs 253 [89%] of 283). With a median follow-up was 78 months (95% CI 75-86), 36-month disease-free survival was 68% (95% CI 63-73) in the irinotecan group versus 67% (61-72) in the standard-of-care group (hazard ratio 0·91 [95% CI 0·68-1·23]; p=0·54). Deaths occurred in 88 (31%) patients in the irinotecan group and 92 (32%) in the standard-of-care group; rectal cancer was the leading cause, occurring in 59 (67%) patients in the irinotecan group and 67 (73%) in the standard-of-care group. There were five deaths related to protocol treatment: three in the irinotecan group (two had a thromboembolic event and one had multiorgan failure plus sepsis) and two in the standard-of-care group (one cardiac arrest and one febrile neutropenia). Grade 3 or worse were more frequent in patients receiving irinotecan than those receiving standard of care (215 [78%] vs 148 [52%]), including haematological investigations (235 [85%] vs 109 [39%]) and gastrointestinal events (57 [21%] vs 35 [12%]), notably diarrhoea (38 [14%] vs ten [4%]), lymphocyte count decreased (181 [66%] vs 100 [35%]), and neutrophil count decreased (27 [10%] vs three [1%]). INTERPRETATION: For MRI-defined, high-risk, locally advanced rectal cancer, the addition of irinotecan to standard of care did not improve outcomes and should not be used in combination with radiotherapy plus capecitabine. FUNDING: Cancer Research UK.
引用
- Sebag-Montefiore D, Adams R, Gollins S, et al. Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2026. PMID: 42508427. doi:10.1016/S1470-2045(26)00132-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。